Scholarlink

Purpose <p>Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) is used for low-grade lumbar spondylolisthesis to reduce access morbidity. However, whether this compromises construct durability versus open surgery (OS) remains uncertain. We conducted a systematic review and meta-analysis to determine whether MIS-TLIF preserves fusion and reoperation outcomes while improving perioperative outcomes compared with OS.</p> Methods <p>PubMed, Embase, and CENTRAL were searched from inception to 1 December 2025. Adult MIS-TLIF was compared with OS-TLIF. Primary outcomes were fusion, overall complications, and reoperation. Secondary outcomes were operative time, blood loss, length of stay (LOS), surgical site infection (SSI), adjacent segment disease, and patient-reported outcomes. Random-effects models were used. Risk of bias (ROBINS-I/RoB) and certainty (GRADE) were assessed.</p> Results <p>Nineteen studies encompassing 2117 patients (MIS 948, OS 1169) were included. Fusion was equivalent (RR 1.13; 95% CI 0.74–1.74; <i>P</i> = 0.51; I<sup>2</sup> = 0.0%). Reoperation was similar (RR 0.72; 95% CI 0.46–1.14; <i>P</i> = 0.13; I<sup>2</sup> = 0.0%), with no evidence of early technical failure in MIS cohorts. MIS reduced overall complications (RR 0.75; 95% CI 0.59–0.95; <i>P</i> = 0.02; I<sup>2</sup> = 0.0%) and SSI (RR 0.30; 95% CI 0.14–0.65; <i>P</i> = 0.007; I<sup>2</sup> = 0.0%). MIS lowered blood loss (MD −194.0 mL; 95% CI −281.98–−106.04; <i>P</i> &lt; 0.001; I<sup>2</sup> = 97.6%) and LOS (MD − 2.1 days; 95% CI −2.92–−1.24; <i>P</i> &lt; 0.001; I<sup>2</sup> = 96.3%). Pain and disability converged by 1–2 years. Most studies had moderate risk of bias; certainty for primary outcomes was moderate overall.</p> Conclusion <p>MIS-TLIF achieves comparable fusion and reoperation outcomes while reducing perioperative burden, consistent with task-contingent, tissue-sparing use in appropriately selected patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Minimally invasive versus open transforaminal lumbar interbody fusion for low grade lumbar spondylolisthesis: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Shaan Patel,
  • Shiva A. Nischal,
  • Griffin W. White,
  • Angelette Mendonca,
  • Gargee Sree Nallanukala,
  • Jack Jallo,
  • James S. Harrop,
  • Srinivas K. Prasad

摘要

Purpose

Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) is used for low-grade lumbar spondylolisthesis to reduce access morbidity. However, whether this compromises construct durability versus open surgery (OS) remains uncertain. We conducted a systematic review and meta-analysis to determine whether MIS-TLIF preserves fusion and reoperation outcomes while improving perioperative outcomes compared with OS.

Methods

PubMed, Embase, and CENTRAL were searched from inception to 1 December 2025. Adult MIS-TLIF was compared with OS-TLIF. Primary outcomes were fusion, overall complications, and reoperation. Secondary outcomes were operative time, blood loss, length of stay (LOS), surgical site infection (SSI), adjacent segment disease, and patient-reported outcomes. Random-effects models were used. Risk of bias (ROBINS-I/RoB) and certainty (GRADE) were assessed.

Results

Nineteen studies encompassing 2117 patients (MIS 948, OS 1169) were included. Fusion was equivalent (RR 1.13; 95% CI 0.74–1.74; P = 0.51; I2 = 0.0%). Reoperation was similar (RR 0.72; 95% CI 0.46–1.14; P = 0.13; I2 = 0.0%), with no evidence of early technical failure in MIS cohorts. MIS reduced overall complications (RR 0.75; 95% CI 0.59–0.95; P = 0.02; I2 = 0.0%) and SSI (RR 0.30; 95% CI 0.14–0.65; P = 0.007; I2 = 0.0%). MIS lowered blood loss (MD −194.0 mL; 95% CI −281.98–−106.04; P < 0.001; I2 = 97.6%) and LOS (MD − 2.1 days; 95% CI −2.92–−1.24; P < 0.001; I2 = 96.3%). Pain and disability converged by 1–2 years. Most studies had moderate risk of bias; certainty for primary outcomes was moderate overall.

Conclusion

MIS-TLIF achieves comparable fusion and reoperation outcomes while reducing perioperative burden, consistent with task-contingent, tissue-sparing use in appropriately selected patients.